Clinical Trial

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This phase III single arm trial determines whether taking prophylactic letermovir will reduce the likelihood of infection with cytomegalovirus (CMV) in children and adolescents after stem cell transplant compared to estimated rate of infection without prophylaxis. The treatments used to prepare for HCT reduce the body's natural infection-fighting ability and increase the likelihood of an infection with a virus called cytomegalovirus. "Prophylaxis" means to take a drug to prevent a disease or side effect. Letermovir is an antiviral drug that stops cytomegalovirus from multiplying and may prevent cytomegalovirus infection and make the disease less severe.
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2023-01-23; most recent amendment 2026-05-01.
Status change: Active, Not Recruiting → Recruiting 2025-12-11
Status change: Recruiting → Active, Not Recruiting 2024-11-14
Status change: Not Yet Recruiting → Recruiting 2024-05-31
Trial Details
NCT Number NCT05711667
Lead Sponsor Children's Oncology Group
Conditions Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Enrollment 105 participants
Start Date 2024-07-11
Primary Completion 2029-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-05